The Role of Androgens in Menopausal Hormone Replacement Therapy

  • Leo PlouffeJr.
  • David P. Cohen
Part of the Clinical Perspectives in Obstetrics and Gynecology book series (CPOG)


The role of androgens in menopausal hormone replacement therapy (HRT) is an area of great controversy. Clinicians range in opinion from those who believe adding androgens is a dangerous and regrettable practice to those who believe that androgenic input is key in maintaining premenopausal energy levels, cognitive function, and libido. The debate is often passionate and dominated by anecdotes rather than a cogent mastery of the available literature. We attempt here to briefly review the available data and formulate practical recommendations.


Obstet Gynecol Free Testosterone Lichen Sclerosis Testosterone Therapy Testosterone Enanthate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab. 1990; 71: 696–704.PubMedCrossRefGoogle Scholar
  2. 2.
    Buster JE, Casson PR, Straughn AB, et al. Postmenopausal steroid replacement with mi-cronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. Am J Obstet Gynecol. 1992; 166: 1163–8.PubMedGoogle Scholar
  3. 3.
    Greenblatt RB. The use of androgens in the menopause and other gynecic disorders. Ob-stet Gynecol Clin North Am. 1987; 14: 251–68.Google Scholar
  4. 4.
    Hughes CL, Wall LL, Creasman WT. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol. 1991; 40: 42–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Cauley JA, Gutal JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol. 1989; 129: 1120–1131.PubMedGoogle Scholar
  6. 6.
    Sherwin BB. Changes in sexual behavior as a function of plasma sex steroid levels in postmenopausal women. Maturitas. 1985; 7 (3): 225–233.PubMedCrossRefGoogle Scholar
  7. 7.
    Sherwin BB, Gelfand MM. Differential symptom response to parenteral estrogen and/ or androgen administration in the surgical menopause. Am J Obstet Gynecol. 1985; 151: 153–60.PubMedGoogle Scholar
  8. 8.
    Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med. 1985; 47: 339–51.PubMedGoogle Scholar
  9. 9.
    Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med. 1987; 49: 397–409.PubMedGoogle Scholar
  10. 10.
    Myers LS, Dixen J, Morrissette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab. 1990; 70: 1124–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinol. 1988; 13: 345–57.CrossRefGoogle Scholar
  12. 12.
    Sherwin BB. Affective changes with estrogen and androgen replacement therapy in surgically menopausal women. J Affective Disord. 1988; 14: 177–87.CrossRefGoogle Scholar
  13. 13.
    Colvard DS, Eriksen EF, Keeting PE, et al. Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Aca Sci. 1989; 86: 854–7.CrossRefGoogle Scholar
  14. 14.
    Girasole G, Jilka RL, Passeri G, et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest. 1992; 89: 883–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Horowitz M, Wishart JM, O’Loughlin PD, Morris HA, Need AG, Nordin BE: Osteoporosis and Klinefelter’s syndrome. Clin Endocrinol. (Oxf) 1992; 36: 113–8.Google Scholar
  16. 16.
    Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 1989; 69: 776–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Garnett T, Studd J, Watson N, Savvas M. A Cross-sectional study of the effects of longterm percutaneous hormone replacement therapy on bone density. Obstet Gynecol. 1991; 78: 1002–1007.PubMedGoogle Scholar
  18. 18.
    Kirkland RT, Keenan BS, Probstfield JL, et al. Decrease in plasma high-density lipoprotein cholesterol levels at puberty in boys with delayed adolescence: correlation with plasma testosterone levels. JAMA. 1987; 257: 502–507.PubMedCrossRefGoogle Scholar
  19. 19.
    Wild RA, Painter PC, Coulson PB, Carruth KB, Ravney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985; 61: 946.PubMedCrossRefGoogle Scholar
  20. 20.
    Gutai J, LaPorte R, Kuller L, Dai W, FalvoGerard L, Caggiula A: Plasma testosterone, high density lipoprotein cholesterol and other lipoprotein fractions. Am J Cardiol. 1981; 48: 897–902.PubMedCrossRefGoogle Scholar
  21. 21.
    Cauley JA, Gutai JP, Kuller LH, Powell JG. The relation of endogenous sex steroid hormone concentrations to serum lipid and lipoprotein levels in postmenopausal women. Am J Epidemiol. 1990; 132: 884–94.PubMedGoogle Scholar
  22. 22.
    DePergola G, DeMitrio V, Perrici A, et al. Influence of free testosterone on antigen levels of plasminogen activator inhibitor-1 in premenopausal women with central obesity. Metabolism. 1982; 41: 131–4.CrossRefGoogle Scholar
  23. 23.
    Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA. 1989; 261: 1165–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Friedl KE, Hannan CJ Jr, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 1990; 39: 69–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Gambrell RD, Teran A: Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. Am J Obstet Gynecol. 1991; 165: 307–17.PubMedGoogle Scholar
  26. 26.
    Sherwin BB, Gelfand MM, Schucher R, Gaborm J. Postmenopausal estrogen and androgern replacement and lipoprotein lipid concentra tions. Am J Obstet Gynecol. 1987; 156: 414–9.PubMedGoogle Scholar
  27. 27.
    Grattarola R, Secreto G, Recchione C. Andro gens in breast cancer, III. Breast cancer recurrences years after mastectomy and increased androgenic activity. Am J Obstet Gynecol. 1975; 121: 169–72.PubMedGoogle Scholar
  28. 28.
    Zumoff B. Hormone profiles and the epidemiology of breast cancer. In Stoll BA, ed. Endocrine Relationships in Breast Cancer. London: William Heinemann Medical Books; 1982: 3–47.Google Scholar
  29. 29.
    Secreto G, Toniolo P, Berrino F, et al. Serum and urinary androgens and risk of breast cancer in postmenopausal women. Cancer Res. 1991; 51: 2572–6.PubMedGoogle Scholar
  30. 30.
    Hill P, Garbaczewski L, Kasumi F. Plasma testosterone and breast cancer. Eur J Cancer Clin Oncol. 1985; 21: 1265–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM: Liver damage from long-term methyltestosterone. Lancet. 1977; 2 (8032): 262–3.PubMedGoogle Scholar
  32. 32.
    Urman B, Pride SM, Ho Yuen B: Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gyne-col. 1991; 77: 595–8.Google Scholar
  33. 33.
    Kashkin KB, Kleber HD. Hooked on hormones?: an anabolic steroid addiction hypothesis. JAMA. 1989; 262: 3166–70.PubMedCrossRefGoogle Scholar
  34. 34.
    Cinberg BL. Postmenopausal pruritus vulvae. Am J Obset Gynecol. 1945; 49: 647.Google Scholar
  35. 35.
    Mann and Cowan. Br J Derm. 1983; 89: 223.CrossRefGoogle Scholar
  36. 36.
    Friedrich EG, Kalra, PS. Serum levels of sex hormones in vulvar lichen sclerosis and the effect of topical testosterone. NEJM. 1984; 310: 488–491.PubMedCrossRefGoogle Scholar
  37. 37.
    Friedrich, EG. Vulvar Dystrophy Clin Obstet Gynecol. 1985; 28 (1): 178–187.CrossRefGoogle Scholar
  38. 38.
    Gadducci A, Facchini V, Del-Bravo B, DellArciprete T, Madrigali A, Fioretti P. The topical administration of steroids in the treatment of typical vulvar dystrophies. Clin Exp Obstet Gynecol. 1989; 16: 12–15.PubMedGoogle Scholar
  39. 39.
    Friedrich EG. Vulvar Dystrophy Clin Obstet Gynecol. 1985; 28 (1): 178–187.CrossRefGoogle Scholar
  40. 40.
    Parker LU, Bergfeld WF. Virilization secondary to topical testosterone. Cleve Clin J Med. 1991; 58: 43–46.PubMedGoogle Scholar
  41. 41.
    Greenblatt RB, Suran RR. Indications for hormonal pellets in the therapy of endocrine and gynecic disorders. Am J Obstet Gynecol. 1949; 57: 294–301.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • Leo PlouffeJr.
  • David P. Cohen

There are no affiliations available

Personalised recommendations